Literature DB >> 12805434

Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.

Wei Ding1, Ziying Yan, Roman Zak, Milene Saavedra, David M Rodman, John F Engelhardt.   

Abstract

Recombinant adeno-associated virus type 5 (rAAV-5) is known to efficiently transduce airway epithelia via apical infection. In contrast, rAAV-2 has been shown to be inherently ineffective at transducing airway epithelia from the apical surface. However, tripeptide proteasome inhibitors (such as LLnL) can dramatically enhance rAAV-2 transduction from the apical surface of human polarized airway epithelia by modulating the intracellular trafficking and processing of the virus. To further investigate potential differences between rAAV-2 and rAAV-5 that might explain their altered ability to transduce airway epithelia from the apical membrane, we examined the functional involvement of the ubiquitin/proteasome pathway and rate-limiting aspects of second-strand synthesis for these two rAAV serotypes. To this end, we conducted studies to compare the extent to which LLnL alters transduction efficiencies with both rAAV-2 and rAAV-2/5 by using luciferase and enhanced green fluorescent protein (EGFP) reporter vectors. Our results demonstrate that the coadministration of LLnL at the time of viral infection significantly enhanced transduction of both rAAV-2/5 and rAAV-2 from the apical surface of airway epithelia. Although rAAV-2/5 was slightly more effective at transducing epithelia from the apical membrane, rAAV-2 transduction was superior to that of rAAV-2/5 in the presence of proteasome inhibitors. Interestingly, the basolateral membrane entry pathways for both serotypes were not significantly affected by the addition of LLnL, which suggests that apical and basolateral infectious pathways possess distinctive intracellular processing pathways for both rAAV-2 and rAAV-5. Studies comparing the transduction of short self-complementary (scAAV) to full-length conventional AAV EGFP vectors suggested that second-strand synthesis of rAAV genomes was not rate limiting for either serotype or altered by proteasome inhibitors following apical infection of polarized airway epithelia. These findings suggest that both rAAV-2 and rAAV-5 share similar intracellular viral processing barriers that involve the ubiquitin/proteasome system, but do not appear to involve second-strand synthesis.

Entities:  

Mesh:

Year:  2003        PMID: 12805434      PMCID: PMC164830          DOI: 10.1128/jvi.77.13.7361-7366.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

2.  Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors.

Authors:  C L Halbert; J M Allen; A D Miller
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 3.  Gene therapy in cystic fibrosis.

Authors:  T R Flotte; B L Laube
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

4.  Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.

Authors:  R W Walters; S M Yi; S Keshavjee; K E Brown; M J Welsh; J A Chiorini; J Zabner
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

5.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.

Authors:  D M McCarty; P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

6.  Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

Authors:  D Duan; Y Yue; Z Yan; J Yang; J F Engelhardt
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.

Authors:  J Zabner; M Seiler; R Walters; R M Kotin; W Fulgeras; B L Davidson; J A Chiorini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

8.  A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

Authors:  M L Aitken; R B Moss; D A Waltz; M E Dovey; M R Tonelli; S C McNamara; R L Gibson; B W Ramsey; B J Carter; T C Reynolds
Journal:  Hum Gene Ther       Date:  2001-10-10       Impact factor: 5.695

9.  Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.

Authors:  F K Ferrari; T Samulski; T Shenk; R J Samulski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

10.  Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins.

Authors:  Alberto Auricchio; Erin O'Connor; Daniel Weiner; Guang-Ping Gao; Markus Hildinger; Lili Wang; Roberto Calcedo; James M Wilson
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

View more
  29 in total

Review 1.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

2.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Mechanistic insights into the enhancement of adeno-associated virus transduction by proteasome inhibitors.

Authors:  Angela M Mitchell; R Jude Samulski
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.

Authors:  Ziying Yan; Diana C M Lei-Butters; Xiaoming Liu; Yulong Zhang; Liang Zhang; Meihui Luo; Roman Zak; John F Engelhardt
Journal:  J Biol Chem       Date:  2006-08-09       Impact factor: 5.157

5.  Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo.

Authors:  Ziying Yan; Diana C M Lei-Butters; Yulong Zhang; Roman Zak; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

6.  Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus.

Authors:  Sarah C Nicolson; R Jude Samulski
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

7.  Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction.

Authors:  Jarrod S Johnson; Chengwen Li; Nina DiPrimio; Marc S Weinberg; Thomas J McCown; R Jude Samulski
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

8.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

9.  Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus.

Authors:  Jarrod S Johnson; R Jude Samulski
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

10.  Biological Differences in rAAV Transduction of Airway Epithelia in Humans and in Old World Non-human Primates.

Authors:  Xiaoming Liu; Meihui Luo; Cyndi Trygg; Ziying Yan; Diana C M Lei-Butters; Carolina I Smith; Anne C Fischer; Keith Munson; William B Guggino; Bruce A Bunnell; John F Engelhardt
Journal:  Mol Ther       Date:  2007-07-31       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.